BRPI0620983B8 - uso de derivados de triazina para fabricação de um medicamento, e composição farmacêutica para uso tópico - Google Patents

uso de derivados de triazina para fabricação de um medicamento, e composição farmacêutica para uso tópico

Info

Publication number
BRPI0620983B8
BRPI0620983B8 BRPI0620983A BRPI0620983A BRPI0620983B8 BR PI0620983 B8 BRPI0620983 B8 BR PI0620983B8 BR PI0620983 A BRPI0620983 A BR PI0620983A BR PI0620983 A BRPI0620983 A BR PI0620983A BR PI0620983 B8 BRPI0620983 B8 BR PI0620983B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
manufacture
triazine derivatives
drug
derivatives
Prior art date
Application number
BRPI0620983A
Other languages
English (en)
Inventor
Cravo Daniel
Moinet Gérard
Original Assignee
Merck Patent Gmbh
Poxel S A S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh, Poxel S A S filed Critical Merck Patent Gmbh
Publication of BRPI0620983A2 publication Critical patent/BRPI0620983A2/pt
Publication of BRPI0620983B1 publication Critical patent/BRPI0620983B1/pt
Publication of BRPI0620983B8 publication Critical patent/BRPI0620983B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

uso de derivados de triazina para a fabricação de um medicamento e composição farmacêutica compreendendo os referidos derivados. a presente invenção refere-se ao uso de derivados de triazina como agentes cicatrizantes ou angiogênicos, bem como a composição farmacêutica cicatrizante ou angiogênica para uso tópico compreendendo, como principio ativo, uma quantidade terapeuticamente eficaz dos referidos derivados.
BRPI0620983A 2006-01-13 2006-12-18 uso de derivados de triazina para fabricação de um medicamento, e composição farmacêutica para uso tópico BRPI0620983B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0600347A FR2896161B1 (fr) 2006-01-13 2006-01-13 Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique.
FR0600347 2006-01-13
PCT/EP2006/012183 WO2007079915A2 (en) 2006-01-13 2006-12-18 Use of triazine derivatives for the manufacture of a medicament having a cicatrising or angiogenic effect

Publications (3)

Publication Number Publication Date
BRPI0620983A2 BRPI0620983A2 (pt) 2011-11-29
BRPI0620983B1 BRPI0620983B1 (pt) 2019-09-17
BRPI0620983B8 true BRPI0620983B8 (pt) 2021-05-25

Family

ID=36658622

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0620983A BRPI0620983B8 (pt) 2006-01-13 2006-12-18 uso de derivados de triazina para fabricação de um medicamento, e composição farmacêutica para uso tópico

Country Status (22)

Country Link
US (1) US8217040B2 (pt)
EP (1) EP1971329B1 (pt)
JP (1) JP2009523140A (pt)
KR (1) KR101482686B1 (pt)
CN (1) CN101355931A (pt)
AR (1) AR059034A1 (pt)
AU (1) AU2006334732B2 (pt)
BR (1) BRPI0620983B8 (pt)
CA (1) CA2636838C (pt)
CY (1) CY1119872T1 (pt)
DK (1) DK1971329T3 (pt)
EA (1) EA016127B1 (pt)
ES (1) ES2647912T3 (pt)
FR (1) FR2896161B1 (pt)
HU (1) HUE037217T2 (pt)
IL (1) IL192595A (pt)
LT (1) LT1971329T (pt)
PL (1) PL1971329T3 (pt)
PT (1) PT1971329T (pt)
SI (1) SI1971329T1 (pt)
WO (1) WO2007079915A2 (pt)
ZA (1) ZA200806946B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2948027A1 (fr) * 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
US11617754B2 (en) 2017-10-02 2023-04-04 Poxel Sa Methods of treating heart failure with preserved ejection fraction
AU2019282727A1 (en) 2018-06-06 2020-11-26 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
SG11202010322XA (en) 2018-06-14 2020-11-27 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
EP4014962A1 (de) * 2020-12-16 2022-06-22 Novigo GmbH & Co. KG Zusammensetzung mit osmotisch wirksamer substanz und verwendung der zusammensetzung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2198088T3 (es) * 1997-12-12 2004-01-16 Abbott Laboratories Inhibidores de la angiogenesis de triazina.
US6150362A (en) * 1997-12-12 2000-11-21 Henkin; Jack Triazine angiogenesis inhibitors
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
CA2510468C (en) * 2002-12-17 2011-01-04 Hamari Chemicals, Ltd. Novel 2,4-diamino-1,3,5-triazine derivative
FR2853650B1 (fr) * 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance

Also Published As

Publication number Publication date
US8217040B2 (en) 2012-07-10
HUE037217T2 (hu) 2018-08-28
EA016127B1 (ru) 2012-02-28
PL1971329T3 (pl) 2018-03-30
EP1971329A2 (en) 2008-09-24
BRPI0620983B1 (pt) 2019-09-17
EA200801678A1 (ru) 2008-12-30
KR20080088629A (ko) 2008-10-02
DK1971329T3 (en) 2017-12-04
AU2006334732B2 (en) 2012-05-17
CA2636838C (en) 2015-05-05
WO2007079915A2 (en) 2007-07-19
AU2006334732A1 (en) 2007-07-19
ES2647912T3 (es) 2017-12-27
BRPI0620983A2 (pt) 2011-11-29
IL192595A0 (en) 2009-02-11
FR2896161A1 (fr) 2007-07-20
ZA200806946B (en) 2009-11-25
US20100168115A1 (en) 2010-07-01
AR059034A1 (es) 2008-03-12
CY1119872T1 (el) 2018-06-27
JP2009523140A (ja) 2009-06-18
SI1971329T1 (en) 2018-03-30
WO2007079915A3 (en) 2007-08-30
KR101482686B1 (ko) 2015-01-14
CN101355931A (zh) 2009-01-28
FR2896161B1 (fr) 2008-04-04
EP1971329B1 (en) 2017-10-11
IL192595A (en) 2013-04-30
PT1971329T (pt) 2017-11-24
CA2636838A1 (en) 2007-07-19
LT1971329T (lt) 2018-01-25

Similar Documents

Publication Publication Date Title
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
BR112015016315A2 (pt) fluoro-[1,3]oxazinas como inibidores de bace1
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112012027034A2 (pt) inibidores da arginase e suas aplicações terapêuticas
BRPI0821115A8 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI0507198A (pt) derivados de bisariluréia
BRPI0610850A2 (pt) derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados
BR112015011171A2 (pt) compostos de pirrolopirimidina como inibidores da quinase
BRPI0714803B8 (pt) compostos peptidomiméticos de smac, seus usos, e composição farmacêutica
BR112012026213A8 (pt) Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa
BRPI0714553B8 (pt) derivados de camptotecina, processo para preparação dos mesmos, composição farmacêutica e seu uso
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
BR112014009415A2 (pt) inibidores de arginase e suas aplicações terapêuticas
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
SV2009003236A (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hematologicas
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
BR0315580A (pt) Derivados de metileno uréia
BR112013026257A2 (pt) derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes
BRPI0908124A2 (pt) Composto, ativador de glucoquinase, composição farmacêutica, uso de um composto ou sal farmacologicamente aceitavél do mesmo, e, métodos de ativação da glucoquinase, e para tratar e/ou prevenir uma doença
BRPI0915064B8 (pt) derivados de quinoxalinadiona, seus usos, e medicamentos
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv
BR112012011793A2 (pt) "acrilamidas heterocíclicas e seu uso como farmacêuticos"
BRPI0720220B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo
SV2010003674A (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: POXEL S.A.S (FR)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/09/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/09/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/12/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2703 DE 25-10-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.